Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management
The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
- The combined European and United States investment syndicate was led by EQT Life Sciences, and co-led by Sectoral, with new investors British Patient Capital, Northern Gritstone and Aphelion/Cardeation Capital also joining the round.
- Patients with swallowing dysfunction (dysphagia) are unable to safely or effectively eat, drink, or manage their own saliva.
- Dysphagia can often lead to life threatening complications such as pneumonia and is also associated with substantially higher healthcare costs.
- Drew Burdon, Partner at EQT Life Sciences, said: "Dysphagia is a severe medical condition that affects countless patients in hospital.